Clinical Trial Update: Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating regorafenib in combination with a PD-1 inhibitor for second-line hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Hepatocellular Carcinoma, Regorafenib | Phase 2 | Status: UNKNOWN